2019
Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance
Shi JM, Henry SP, Dwy SL, Orazietti SA, Carroll KM. Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance. Substance Abuse 2019, 40: 132-135. PMID: 30714880, PMCID: PMC6874094, DOI: 10.1080/08897077.2019.1569192.Peer-Reviewed Original ResearchConceptsOffice-based buprenorphineOpioid use disorderBuprenorphine treatmentWeb-based interventionBuprenorphine maintenancePilot trialUse disordersBehavioral careCurrent opioid use disorderOffice-based buprenorphine treatmentUrine toxicology screenSpecific patient populationsDays of treatmentDSM-5 criteriaCognitive behavioral therapyInitial pilot testingToxicology screenPatient populationTwelve-weekEffective treatmentBuprenorphineDrug useSmall sample sizeTrialsPromising findings
2018
An investigation of an open‐access model for scaling up methadone maintenance treatment
Madden LM, Farnum SO, Eggert KF, Quanbeck AR, Freeman RM, Ball SA, Schottenfeld RS, Shi JM, Savage ME, Barry DT. An investigation of an open‐access model for scaling up methadone maintenance treatment. Addiction 2018, 113: 1450-1458. PMID: 29453891, DOI: 10.1111/add.14198.Peer-Reviewed Original ResearchConceptsNon-medical opioid useOpioid use disorderMethadone maintenance treatmentOpioid useMaintenance treatmentTreatment accessUse disordersTreatment modelMethadone maintenance treatment centersMaintenance treatment centersDeleterious effectsMethadone treatmentPatient mortalityTreatment optionsTreatment outcomesTreatment centersProspective patientsRate of retentionPatient censusRapid enrollmentAddiction treatmentApparent deleterious effectsTreatmentMortalityProgrammatic outcomes
2017
Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. PMID: 28237054, DOI: 10.1016/j.jsat.2016.12.014.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOpioid treatment programsPercent of patientsHCV treatmentHCV infectionActing antiviralsTreatment outcomesTreatment programOral HCV treatmentSustained virologic responseHCV treatment outcomesRoutine clinical careOngoing drug useVirologic responseRetrospective studyClinical careGeneral populationPatientsDrug useTreatmentOutcomesAntiviralsInfectionPercentPWID
2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms
2001
Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement
Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement. JAMA Psychiatry 2001, 58: 755-761. PMID: 11483141, PMCID: PMC3651594, DOI: 10.1001/archpsyc.58.8.755.Peer-Reviewed Original ResearchConceptsDrug-free urine specimensNaltrexone treatmentFamily counseling sessionsContingency managementOpioid dependenceTreatment retentionUrine specimensBehavioral therapyOpioid-dependent individualsCounseling sessionsDrug use outcomesSubstance abuse outcomesNaltrexone complianceNaltrexone therapyOpioid useAvailable pharmacotherapiesMedication complianceSpecific pharmacotherapySignificant improvementTherapyUse outcomesAbuse outcomesPrincipal outcomePharmacotherapyTreatment
1999
Tuberculosis chemoprophylaxis using a liquid isoniazid‐methadone admixture for drug users in methadone maintenance
O'Connor PG, Shi JM, Henry S, Durante AJ, Friedman L, Selwyn PA. Tuberculosis chemoprophylaxis using a liquid isoniazid‐methadone admixture for drug users in methadone maintenance. Addiction 1999, 94: 1071-1075. PMID: 10707445, DOI: 10.1046/j.1360-0443.1999.947107112.x.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsCohort StudiesDrug CombinationsFemaleHumansIsoniazidMaleMethadoneNarcoticsOpioid-Related DisordersPatient CompliancePyridoxineTuberculosisUnited StatesConceptsMethadone maintenanceTuberculosis chemoprophylaxisDrug usersMedian durationDaily doseOpioid-dependent drug usersProspective cohort studyMethadone maintenance programDrug treatment programsCompleting therapyINH chemoprophylaxisINH prophylaxisCohort studyEligible subjectsINH therapyCommon reasonChemoprophylaxisTherapyVitamin B6Treatment programMethadoneIsoniazidSubjectsINHDuration